Biotech

All Articles

Lilly posts much more positive records on its own weekly insulin possibility

.On the heels of an FDA denial for its primary rivalrous Novo Nordisk, Eli Lilly is pushing on in th...

IN 8bio stops phase 2 trial, gives up one-half of labor force

.Just a couple of months after dosing the very first patient in a phase 2 test for freshly diagnosed...

Lilly, Haya ink $1B biobuck being overweight treaty to browse black genome

.Eli Lilly's search for obesity targets has led it to the darker genome. The Big Pharma has actually...

ArsenalBio increases $325M, turns far from previous lead asset

.Toolbox Biosciences is actually proceeding up. The tissue therapy business has actually added $325 ...

Lilly- supported fat burning biotech reports IPO

.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has actually...

Aelis' marijuana use medicine flunks phase 2b, driving Indivior to reassess $100M option

.Aelis Farma's hopes of securing a fast, good decision on a $100 million possibility remittance have...

ProKidney halts phase 3 test not needed for cell treatment approval

.ProKidney has actually quit some of a set of phase 3 tests for its own cell treatment for renal ill...

Vaxcyte rises on 'stunning' 31-valent PCV succeed versus Pfizer

.Vaxcyte revealed what analysts named "spectacular" period 1/2 records for its 31-valent pneumococca...

Recursion's brain illness test presents scant evidence of efficiency

.Recursion has actually stumbled with a very early test of its tech-enabled strategy to drug explora...

Acepodia, Pfizer click on together for chemistry-based tissue treatment

.Call it a situation of good chemical make up: Acepodia, a biotech based on Nobel Champion scientifi...